MX2014012376A - Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio. - Google Patents

Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio.

Info

Publication number
MX2014012376A
MX2014012376A MX2014012376A MX2014012376A MX2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A
Authority
MX
Mexico
Prior art keywords
day
colchicine
therapeutic agent
halofenate
subject
Prior art date
Application number
MX2014012376A
Other languages
English (en)
Spanish (es)
Inventor
Brian Edward Lavan
Gopal Chandra Saha
Brian K Roberts
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2014012376A publication Critical patent/MX2014012376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014012376A 2012-04-13 2013-04-12 Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio. MX2014012376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624186P 2012-04-13 2012-04-13
PCT/US2013/036474 WO2013155478A1 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
MX2014012376A true MX2014012376A (es) 2015-06-05

Family

ID=49325641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012376A MX2014012376A (es) 2012-04-13 2013-04-12 Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio.

Country Status (15)

Country Link
US (1) US20130274331A1 (enExample)
EP (1) EP2836209A4 (enExample)
JP (1) JP2015512948A (enExample)
KR (1) KR20150002799A (enExample)
CN (1) CN104602686A (enExample)
AU (1) AU2013245675B2 (enExample)
CA (1) CA2870014A1 (enExample)
CL (1) CL2014002728A1 (enExample)
EA (1) EA028495B1 (enExample)
HK (1) HK1204913A1 (enExample)
IL (1) IL235154A0 (enExample)
MX (1) MX2014012376A (enExample)
PH (1) PH12014502282A1 (enExample)
SG (1) SG11201406495UA (enExample)
WO (1) WO2013155478A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2900740T3 (es) 2012-11-02 2022-03-18 Murray & Poole Entpr Ltd Tratamiento o prevención de episodios cardiovasculares mediante la administración de colchicina
WO2014170755A2 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
JP2023035118A (ja) * 2021-08-31 2023-03-13 国立大学法人広島大学 体液サンプリング容器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
CA2716860C (en) * 2008-03-13 2017-08-29 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
US20090232745A1 (en) * 2008-03-14 2009-09-17 Intelliherb, Inc. Licorice lollipop that inhibits dental caries formation
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
DK2775836T3 (en) * 2011-11-04 2018-12-03 Cymabay Therapeutics Inc PROCEDURES FOR TREATING GIG RETURN
CA2859689C (en) * 2011-11-04 2018-05-22 Cymabay Therapeutics, Inc. Methods for treating gout in patient subpopulations
CN109908124A (zh) * 2011-11-04 2019-06-21 西玛贝医药公司 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法

Also Published As

Publication number Publication date
US20130274331A1 (en) 2013-10-17
PH12014502282A1 (en) 2014-12-15
JP2015512948A (ja) 2015-04-30
WO2013155478A1 (en) 2013-10-17
EP2836209A4 (en) 2015-11-25
CL2014002728A1 (es) 2015-06-19
HK1204913A1 (en) 2015-12-11
SG11201406495UA (en) 2014-11-27
CN104602686A (zh) 2015-05-06
EA028495B1 (ru) 2017-11-30
IL235154A0 (en) 2014-12-31
KR20150002799A (ko) 2015-01-07
EA201491870A1 (ru) 2015-03-31
AU2013245675B2 (en) 2017-02-09
AU2013245675A1 (en) 2014-10-30
CA2870014A1 (en) 2013-10-17
EP2836209A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
JP6008974B2 (ja) 痛風発赤の治療方法
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
AU2011380507B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法